Titan Pharmaceuticals, Inc. (TTNP) 10-Year Financial Performance & Capital Metrics

TTNP • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutTitan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.Show more

Revenue $0 -100.0%
EBITDA -$5M +36.5%
Net Income -$5M +15.5%
EPS (Diluted) -5.23 +29.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -103.63% +25.5%
ROIC -12206.25%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Shares diluted 19.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-88.24%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM48.64%

EPS CAGR

10Y-

5Y-

3Y-

TTM54.15%

ROCE

10Y Avg-143.02%

5Y Avg-187.53%

3Y Avg-194.61%

Latest-100.35%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.67M	15.06M	215K	5.91M	3.61M	4.84M	1.53M	60K	1K	0
Revenue Growth %	-0.54%	8.02%	-0.99%	26.49%	-0.39%	0.34%	-0.68%	-0.96%	-0.98%	-1%
Cost of Goods Sold+	4.67M	6.13M	9.65M	538K	1.29M	472K	199K	196K	0	5K
COGS % of Revenue	2.8%	0.41%	44.87%	0.09%	0.36%	0.1%	0.13%	3.27%	-	-
Gross Profit+	-3M	8.94M	-9.43M	5.37M	2.32M	4.37M	1.33M	-136K	1K	-5K
Gross Margin %	-1.8%	0.59%	-43.87%	0.91%	0.64%	0.9%	0.87%	-2.27%	1%	-
Gross Profit Growth %	-6%	3.98%	-2.06%	1.57%	-0.57%	0.88%	-0.7%	-1.1%	1.01%	-6%
Operating Expenses+	8.43M	10.72M	14.72M	13.64M	19.17M	11.72M	10.68M	10.29M	7.28M	4.56M
OpEx % of Revenue	5.04%	0.71%	68.45%	2.31%	5.31%	2.42%	7%	171.58%	7278%	-
Selling, General & Admin	3.75M	4.6M	5.07M	6.87M	11.93M	5.8M	4.99M	6.03M	5.55M	4.56M
SG&A % of Revenue	2.25%	0.31%	23.58%	1.16%	3.3%	1.2%	3.27%	100.57%	5548%	-
Research & Development	4.67M	6.13M	9.65M	7.48M	7.24M	5.92M	5.69M	4.76M	1.91M	0
R&D % of Revenue	2.8%	0.41%	44.87%	1.27%	2.01%	1.22%	3.73%	79.3%	1913%	-
Other Operating Expenses	0	0	-55K	-6K	17K	0	-84K	-497K	-183K	0
Operating Income+	-6.76M	4.34M	-14.5M	-8.26M	-16.84M	-7.35M	-9.35M	-10.23M	-7.28M	-4.56M
Operating Margin %	-4.04%	0.29%	-67.45%	-1.4%	-4.66%	-1.52%	-6.13%	-170.58%	-7277%	-
Operating Income Growth %	-0.95%	1.64%	-4.34%	0.43%	-1.04%	0.56%	-0.27%	-0.09%	0.29%	0.37%
EBITDA+	-6.4M	4.72M	-14.09M	-7.88M	-16.6M	-7.06M	-9.13M	-10.04M	-7.17M	-4.55M
EBITDA Margin %	-3.83%	0.31%	-65.51%	-1.33%	-4.6%	-1.46%	-5.98%	-167.32%	-7165%	-
EBITDA Growth %	-1.05%	1.74%	-3.98%	0.44%	-1.11%	0.57%	-0.29%	-0.1%	0.29%	0.36%
D&A (Non-Cash Add-back)	358K	377K	417K	380K	244K	292K	221K	196K	112K	5K
EBIT	-6.76M	4.34M	-14.5M	-8.26M	-6.52M	-7.35M	-9.35M	-10.23M	-7.28M	-4.71M
Net Interest Income+	0	37K	-369K	-887K	-967K	-769K	1K	53K	5K	1K
Interest Income	0	0	0	0	0	0	1K	53K	5K	1K
Interest Expense	0	37K	369K	887K	967K	769K	0	0	0	0
Other Income/Expense	-4.52M	792K	195K	-759K	386K	-56K	578K	29K	1.71M	-149K
Pretax Income+	-11.28M	5.13M	-14.31M	-9.02M	-16.46M	-7.41M	-8.78M	-10.21M	-5.57M	-4.71M
Pretax Margin %	-6.75%	0.34%	-66.54%	-1.53%	-4.56%	-1.53%	-5.75%	-170.1%	-5569%	-
Income Tax+	0	0	0	0	-369K	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.98%	2.8%	0.92%	1%	1%	1%
Net Income+	-11.28M	5.13M	-14.31M	-9.02M	-16.09M	-20.73M	-8.11M	-10.18M	-5.57M	-4.71M
Net Margin %	-6.75%	0.34%	-66.54%	-1.53%	-4.46%	-4.28%	-5.32%	-169.62%	-5569%	-
Net Income Growth %	-3.69%	1.46%	-3.79%	0.37%	-0.78%	-0.29%	0.61%	-0.25%	0.45%	0.15%
Net Income (Continuing)	-11.28M	5.13M	-14.31M	-9.02M	-7.49M	-7.41M	-8.78M	-10.21M	-5.57M	-4.71M
Discontinued Operations	0	0	0	0	0	-10.84M	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-101.24	36.01	-121.34	-47.59	-9.83	-10.38	-4.06	-15.15	-7.41	-5.23
EPS Growth %	-2.99%	1.36%	-4.37%	0.61%	0.79%	-0.06%	0.61%	-2.73%	0.51%	0.29%
EPS (Basic)	-101.24	44.71	-121.48	-47.59	-12602.35	-10.38	-4.06	-15.15	-7.41	-5.23
Diluted Shares Outstanding	111.4K	119.21K	117.91K	189.6K	1.64M	2M	2M	671.7K	752K	899K
Basic Shares Outstanding	111.4K	115.21K	117.78K	189.6K	1.28K	2M	2M	671.7K	752K	899K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	12.24M	17.83M	8.31M	13.3M	8.31M	7.33M	7.23M	3.6M	8.02M	2.92M
Cash & Short-Term Investments	7.86M	14.01M	7.52M	9.29M	5.22M	5.41M	6.04M	2.94M	6.76M	2.83M
Cash Only	7.86M	14.01M	7.52M	9.29M	5.22M	5.41M	6.04M	2.94M	6.76M	2.83M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	4.21M	3.59M	65K	1.84M	438K	884K	112K	36K	1.05M	62K
Days Sales Outstanding	920.25	86.91	110.35	113.37	44.27	66.69	26.79	219	381.79K	-
Inventory	0	0	0	1.26M	998K	328K	293K	106K	0	0
Days Inventory Outstanding	-	-	-	856.19	282.82	253.64	537.41	197.4	-	-
Other Current Assets	174K	237K	361K	361K	1.55M	181K	307K	524K	212K	30K
Total Non-Current Assets+	1.04M	837K	595K	794K	1.21M	759K	765K	455K	68K	0
Property, Plant & Equipment	1.04M	837K	595K	794K	1.21M	759K	717K	407K	68K	0
Fixed Asset Turnover	1.60x	18.00x	0.36x	7.44x	2.97x	6.37x	2.13x	0.15x	0.01x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	-1.21M	-759K	48K	48K	0	0
Total Assets+	13.29M	18.67M	8.9M	14.1M	9.52M	8.09M	7.99M	4.06M	8.09M	2.92M
Asset Turnover	0.13x	0.81x	0.02x	0.42x	0.38x	0.60x	0.19x	0.01x	0.00x	-
Asset Growth %	-0.36%	0.4%	-0.52%	0.58%	-0.32%	-0.15%	-0.01%	-0.49%	0.99%	-0.64%
Total Current Liabilities+	4.85M	4.86M	4.46M	3.45M	3.6M	4.22M	2.67M	2.63M	1.44M	483K
Accounts Payable	4.16M	3.02M	821K	1.53M	815K	1.25M	795K	695K	348K	202K
Days Payables Outstanding	324.64	179.64	31.06	1.04K	230.96	968.95	1.46K	1.29K	-	14.75K
Short-Term Debt	0	0	3M	527K	272K	477K	112K	0	500K	0
Deferred Revenue (Current)	0	0	0	313K	0	533K	295K	196K	12K	0
Other Current Liabilities	0	0	0	0	1.81M	1.81M	1.03M	129K	0	0
Current Ratio	2.52x	3.67x	1.86x	3.85x	2.31x	1.74x	2.71x	1.37x	5.55x	6.05x
Quick Ratio	2.52x	3.67x	1.86x	3.49x	2.03x	1.66x	2.60x	1.33x	5.55x	6.05x
Cash Conversion Cycle	-	-	-	-65.74	96.13	-648.61	-893.96	-877.86	-	-
Total Non-Current Liabilities+	1.44M	619K	3.58M	3.81M	4.49M	332K	187K	65K	0	0
Long-Term Debt	0	0	3.58M	3.79M	4.02M	332K	0	0	0	0
Capital Lease Obligations	0	0	0	0	150K	0	187K	65K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.44M	619K	0	25K	320K	0	0	0	0	0
Total Liabilities	6.3M	5.48M	8.05M	7.26M	8.09M	4.55M	2.86M	2.69M	1.44M	483K
Total Debt+	0	0	6.58M	4.31M	4.44M	809K	299K	187K	565K	0
Net Debt	-7.86M	-14.01M	-938K	-4.98M	-782K	-4.6M	-5.74M	-2.75M	-6.2M	-2.83M
Debt / Equity	-	-	7.68x	0.63x	3.10x	0.23x	0.06x	0.14x	0.09x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-2.97x	-	-	-	-	-	-	-	-
Interest Coverage	-	117.38x	-39.30x	-9.32x	-17.42x	-9.56x	-	-	-	-
Total Equity+	6.99M	13.19M	857K	6.83M	1.43M	3.53M	5.14M	1.36M	6.64M	2.44M
Equity Growth %	-0.19%	0.89%	-0.94%	6.97%	-0.79%	1.46%	0.45%	-0.73%	3.87%	-0.63%
Book Value per Share	62.74	110.66	7.27	36.03	0.88	1.77	2.57	2.03	8.83	2.71
Total Shareholders' Equity	6.99M	13.19M	857K	6.83M	1.43M	3.53M	5.14M	1.36M	6.64M	2.44M
Common Stock	297.83M	297.86M	297.86M	13K	57K	7K	10K	1K	1K	1K
Retained Earnings	-314.1M	-308.96M	-323.27M	-332.58M	-349.04M	-367.28M	-376.06M	-386.26M	-391.83M	-396.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3.27M	-3.64M	-4.06M	-4.44M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.47M	6.29M	-13.04M	-8.43M	-15.45M	-17.2M	-7.9M	-8.18M	-7.09M	-3.88M
Operating CF Margin %	-4.47%	0.42%	-60.64%	-1.43%	-4.28%	-3.56%	-5.18%	-136.38%	-7092%	-
Operating CF Growth %	-0.27%	1.84%	-3.07%	0.35%	-0.83%	-0.11%	0.54%	-0.04%	0.13%	0.45%
Net Income	-11.28M	5.13M	-14.31M	-9.02M	-16.46M	-18.24M	-8.78M	-10.21M	-5.57M	-4.71M
Depreciation & Amortization	358K	377K	417K	380K	244K	292K	221K	196K	112K	5K
Stock-Based Compensation	1.03M	1.04M	1.69M	1.56M	572K	7K	1.5M	997K	1.01M	0
Deferred Taxes	0	-1.04M	-619K	-134K	-1.34M	-760K	-661K	0	0	0
Other Non-Cash Items	4.51M	214K	141K	-803K	572K	482K	-5K	452K	-1.73M	-2K
Working Capital Changes	-2.08M	567K	-357K	-408K	961K	1.02M	-219K	378K	-916K	823K
Change in Receivables	-245K	-245K	3.52M	-1.67M	744K	186K	642K	76K	-10K	1.05M
Change in Inventory	83K	0	0	31K	264K	287K	35K	187K	0	0
Change in Payables	-250K	-1.14M	-2.19M	542K	-125K	1.1M	-1.19M	-751K	-476K	-145K
Cash from Investing+	-133K	-171K	-175K	-416K	-256K	-540K	-23K	0	732K	0
Capital Expenditures	-133K	-171K	-175K	-416K	-256K	-540K	-23K	0	-2K	0
CapEx % of Revenue	0.08%	0.01%	0.81%	0.07%	0.07%	0.11%	0.02%	-	2%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-133K	-133K	-175K	-579K	-267K	-540K	-23K	0	734K	0
Cash from Financing+	-14K	27K	6.73M	10.62M	11.27M	17.93M	8.84M	4.98M	10M	-62K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-285K	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	27K	0	3.6M	1.6M	7.24M	0	4K	0	-62K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.6M	6.12M	-13.21M	-8.85M	-15.7M	-17.74M	-7.92M	-8.18M	-7.09M	-3.88M
FCF Margin %	-4.55%	0.41%	-61.46%	-1.5%	-4.35%	-3.67%	-5.19%	-136.38%	-7094%	-
FCF Growth %	-0.29%	1.81%	-3.16%	0.33%	-0.77%	-0.13%	0.55%	-0.03%	0.13%	0.45%
FCF per Share	-68.21	51.36	-112.06	-46.66	-9.60	-8.88	-3.97	-12.18	-9.43	-4.32
FCF Conversion (FCF/Net Income)	0.66x	1.23x	0.91x	0.93x	0.96x	0.83x	0.97x	0.80x	1.27x	0.82x
Interest Paid	0	0	298K	471K	432K	295K	0	0	21K	13K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-144.59%	50.89%	-203.69%	-234.73%	-389.38%	-834.96%	-187.17%	-313.09%	-139.14%	-103.63%
Return on Invested Capital (ROIC)	-	-	-	-700.73%	-1010.24%	-	-	-	-	-12206.25%
Gross Margin	-179.77%	59.34%	-4387.44%	90.9%	64.33%	90.24%	86.96%	-226.67%	100%	-
Net Margin	-674.99%	34.09%	-6654.42%	-152.65%	-445.56%	-428.44%	-531.72%	-16961.67%	-556900%	-
Debt / Equity	-	-	7.68x	0.63x	3.10x	0.23x	0.06x	0.14x	0.09x	-
Interest Coverage	-	117.38x	-39.30x	-9.32x	-17.42x	-9.56x	-	-	-	-
FCF Conversion	0.66x	1.23x	0.91x	0.93x	0.96x	0.83x	0.97x	0.80x	1.27x	0.82x
Revenue Growth	-54.17%	801.56%	-98.57%	2649.3%	-38.91%	33.98%	-68.46%	-96.07%	-98.33%	-100%

Revenue by Segment

	2019	2020	2021	2022	2023
Grant	2.29M	4.3M	-	497K	183K
Grant Growth	-	87.73%	-	-	-63.18%
License and Service	-	-	-	60K	1K
License and Service Growth	-	-	-	-	-98.33%
Grant revenue	-	-	1.28M	-	-
Grant revenue Growth	-	-	-	-	-
Product revenue	-	-	236K	-	-
Product revenue Growth	-	-	-	-	-
License revenue	-	-	13K	-	-
License revenue Growth	-	-	-	-	-
Manufactured Product Other	1.01M	528K	-	-	-
Manufactured Product Other Growth	-	-47.51%	-	-	-
License And Service	315K	11K	-	-	-
License And Service Growth	-	-96.51%	-	-	-

Frequently Asked Questions

Growth & Financials

Titan Pharmaceuticals, Inc. (TTNP) reported $0.0M in revenue for fiscal year 2024. This represents a 100% decrease from $4.1M in 2011.

Titan Pharmaceuticals, Inc. (TTNP) saw revenue decline by 100.0% over the past year.

Titan Pharmaceuticals, Inc. (TTNP) reported a net loss of $2.8M for fiscal year 2024.

Dividend & Returns

Titan Pharmaceuticals, Inc. (TTNP) has a return on equity (ROE) of -103.6%. Negative ROE indicates the company is unprofitable.

Titan Pharmaceuticals, Inc. (TTNP) had negative free cash flow of $2.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Titan Pharmaceuticals, Inc. (TTNP) 10-Year Financial Performance & Capital Metrics

TTNP • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $0 -100.0%
EBITDA -$5M +36.5%
Net Income -$5M +15.5%
EPS (Diluted) -5.23 +29.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -103.63% +25.5%
ROIC -12206.25%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Shares diluted 19.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-88.24%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM48.64%

EPS CAGR

10Y-

5Y-

3Y-

TTM54.15%

ROCE

10Y Avg-143.02%

5Y Avg-187.53%

3Y Avg-194.61%

Latest-100.35%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.67M	15.06M	215K	5.91M	3.61M	4.84M	1.53M	60K	1K	0
Revenue Growth %	-0.54%	8.02%	-0.99%	26.49%	-0.39%	0.34%	-0.68%	-0.96%	-0.98%	-1%
Cost of Goods Sold+	4.67M	6.13M	9.65M	538K	1.29M	472K	199K	196K	0	5K
COGS % of Revenue	2.8%	0.41%	44.87%	0.09%	0.36%	0.1%	0.13%	3.27%	-	-
Gross Profit+	-3M	8.94M	-9.43M	5.37M	2.32M	4.37M	1.33M	-136K	1K	-5K
Gross Margin %	-1.8%	0.59%	-43.87%	0.91%	0.64%	0.9%	0.87%	-2.27%	1%	-
Gross Profit Growth %	-6%	3.98%	-2.06%	1.57%	-0.57%	0.88%	-0.7%	-1.1%	1.01%	-6%
Operating Expenses+	8.43M	10.72M	14.72M	13.64M	19.17M	11.72M	10.68M	10.29M	7.28M	4.56M
OpEx % of Revenue	5.04%	0.71%	68.45%	2.31%	5.31%	2.42%	7%	171.58%	7278%	-
Selling, General & Admin	3.75M	4.6M	5.07M	6.87M	11.93M	5.8M	4.99M	6.03M	5.55M	4.56M
SG&A % of Revenue	2.25%	0.31%	23.58%	1.16%	3.3%	1.2%	3.27%	100.57%	5548%	-
Research & Development	4.67M	6.13M	9.65M	7.48M	7.24M	5.92M	5.69M	4.76M	1.91M	0
R&D % of Revenue	2.8%	0.41%	44.87%	1.27%	2.01%	1.22%	3.73%	79.3%	1913%	-
Other Operating Expenses	0	0	-55K	-6K	17K	0	-84K	-497K	-183K	0
Operating Income+	-6.76M	4.34M	-14.5M	-8.26M	-16.84M	-7.35M	-9.35M	-10.23M	-7.28M	-4.56M
Operating Margin %	-4.04%	0.29%	-67.45%	-1.4%	-4.66%	-1.52%	-6.13%	-170.58%	-7277%	-
Operating Income Growth %	-0.95%	1.64%	-4.34%	0.43%	-1.04%	0.56%	-0.27%	-0.09%	0.29%	0.37%
EBITDA+	-6.4M	4.72M	-14.09M	-7.88M	-16.6M	-7.06M	-9.13M	-10.04M	-7.17M	-4.55M
EBITDA Margin %	-3.83%	0.31%	-65.51%	-1.33%	-4.6%	-1.46%	-5.98%	-167.32%	-7165%	-
EBITDA Growth %	-1.05%	1.74%	-3.98%	0.44%	-1.11%	0.57%	-0.29%	-0.1%	0.29%	0.36%
D&A (Non-Cash Add-back)	358K	377K	417K	380K	244K	292K	221K	196K	112K	5K
EBIT	-6.76M	4.34M	-14.5M	-8.26M	-6.52M	-7.35M	-9.35M	-10.23M	-7.28M	-4.71M
Net Interest Income+	0	37K	-369K	-887K	-967K	-769K	1K	53K	5K	1K
Interest Income	0	0	0	0	0	0	1K	53K	5K	1K
Interest Expense	0	37K	369K	887K	967K	769K	0	0	0	0
Other Income/Expense	-4.52M	792K	195K	-759K	386K	-56K	578K	29K	1.71M	-149K
Pretax Income+	-11.28M	5.13M	-14.31M	-9.02M	-16.46M	-7.41M	-8.78M	-10.21M	-5.57M	-4.71M
Pretax Margin %	-6.75%	0.34%	-66.54%	-1.53%	-4.56%	-1.53%	-5.75%	-170.1%	-5569%	-
Income Tax+	0	0	0	0	-369K	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.98%	2.8%	0.92%	1%	1%	1%
Net Income+	-11.28M	5.13M	-14.31M	-9.02M	-16.09M	-20.73M	-8.11M	-10.18M	-5.57M	-4.71M
Net Margin %	-6.75%	0.34%	-66.54%	-1.53%	-4.46%	-4.28%	-5.32%	-169.62%	-5569%	-
Net Income Growth %	-3.69%	1.46%	-3.79%	0.37%	-0.78%	-0.29%	0.61%	-0.25%	0.45%	0.15%
Net Income (Continuing)	-11.28M	5.13M	-14.31M	-9.02M	-7.49M	-7.41M	-8.78M	-10.21M	-5.57M	-4.71M
Discontinued Operations	0	0	0	0	0	-10.84M	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-101.24	36.01	-121.34	-47.59	-9.83	-10.38	-4.06	-15.15	-7.41	-5.23
EPS Growth %	-2.99%	1.36%	-4.37%	0.61%	0.79%	-0.06%	0.61%	-2.73%	0.51%	0.29%
EPS (Basic)	-101.24	44.71	-121.48	-47.59	-12602.35	-10.38	-4.06	-15.15	-7.41	-5.23
Diluted Shares Outstanding	111.4K	119.21K	117.91K	189.6K	1.64M	2M	2M	671.7K	752K	899K
Basic Shares Outstanding	111.4K	115.21K	117.78K	189.6K	1.28K	2M	2M	671.7K	752K	899K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	12.24M	17.83M	8.31M	13.3M	8.31M	7.33M	7.23M	3.6M	8.02M	2.92M
Cash & Short-Term Investments	7.86M	14.01M	7.52M	9.29M	5.22M	5.41M	6.04M	2.94M	6.76M	2.83M
Cash Only	7.86M	14.01M	7.52M	9.29M	5.22M	5.41M	6.04M	2.94M	6.76M	2.83M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	4.21M	3.59M	65K	1.84M	438K	884K	112K	36K	1.05M	62K
Days Sales Outstanding	920.25	86.91	110.35	113.37	44.27	66.69	26.79	219	381.79K	-
Inventory	0	0	0	1.26M	998K	328K	293K	106K	0	0
Days Inventory Outstanding	-	-	-	856.19	282.82	253.64	537.41	197.4	-	-
Other Current Assets	174K	237K	361K	361K	1.55M	181K	307K	524K	212K	30K
Total Non-Current Assets+	1.04M	837K	595K	794K	1.21M	759K	765K	455K	68K	0
Property, Plant & Equipment	1.04M	837K	595K	794K	1.21M	759K	717K	407K	68K	0
Fixed Asset Turnover	1.60x	18.00x	0.36x	7.44x	2.97x	6.37x	2.13x	0.15x	0.01x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	-1.21M	-759K	48K	48K	0	0
Total Assets+	13.29M	18.67M	8.9M	14.1M	9.52M	8.09M	7.99M	4.06M	8.09M	2.92M
Asset Turnover	0.13x	0.81x	0.02x	0.42x	0.38x	0.60x	0.19x	0.01x	0.00x	-
Asset Growth %	-0.36%	0.4%	-0.52%	0.58%	-0.32%	-0.15%	-0.01%	-0.49%	0.99%	-0.64%
Total Current Liabilities+	4.85M	4.86M	4.46M	3.45M	3.6M	4.22M	2.67M	2.63M	1.44M	483K
Accounts Payable	4.16M	3.02M	821K	1.53M	815K	1.25M	795K	695K	348K	202K
Days Payables Outstanding	324.64	179.64	31.06	1.04K	230.96	968.95	1.46K	1.29K	-	14.75K
Short-Term Debt	0	0	3M	527K	272K	477K	112K	0	500K	0
Deferred Revenue (Current)	0	0	0	313K	0	533K	295K	196K	12K	0
Other Current Liabilities	0	0	0	0	1.81M	1.81M	1.03M	129K	0	0
Current Ratio	2.52x	3.67x	1.86x	3.85x	2.31x	1.74x	2.71x	1.37x	5.55x	6.05x
Quick Ratio	2.52x	3.67x	1.86x	3.49x	2.03x	1.66x	2.60x	1.33x	5.55x	6.05x
Cash Conversion Cycle	-	-	-	-65.74	96.13	-648.61	-893.96	-877.86	-	-
Total Non-Current Liabilities+	1.44M	619K	3.58M	3.81M	4.49M	332K	187K	65K	0	0
Long-Term Debt	0	0	3.58M	3.79M	4.02M	332K	0	0	0	0
Capital Lease Obligations	0	0	0	0	150K	0	187K	65K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.44M	619K	0	25K	320K	0	0	0	0	0
Total Liabilities	6.3M	5.48M	8.05M	7.26M	8.09M	4.55M	2.86M	2.69M	1.44M	483K
Total Debt+	0	0	6.58M	4.31M	4.44M	809K	299K	187K	565K	0
Net Debt	-7.86M	-14.01M	-938K	-4.98M	-782K	-4.6M	-5.74M	-2.75M	-6.2M	-2.83M
Debt / Equity	-	-	7.68x	0.63x	3.10x	0.23x	0.06x	0.14x	0.09x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-2.97x	-	-	-	-	-	-	-	-
Interest Coverage	-	117.38x	-39.30x	-9.32x	-17.42x	-9.56x	-	-	-	-
Total Equity+	6.99M	13.19M	857K	6.83M	1.43M	3.53M	5.14M	1.36M	6.64M	2.44M
Equity Growth %	-0.19%	0.89%	-0.94%	6.97%	-0.79%	1.46%	0.45%	-0.73%	3.87%	-0.63%
Book Value per Share	62.74	110.66	7.27	36.03	0.88	1.77	2.57	2.03	8.83	2.71
Total Shareholders' Equity	6.99M	13.19M	857K	6.83M	1.43M	3.53M	5.14M	1.36M	6.64M	2.44M
Common Stock	297.83M	297.86M	297.86M	13K	57K	7K	10K	1K	1K	1K
Retained Earnings	-314.1M	-308.96M	-323.27M	-332.58M	-349.04M	-367.28M	-376.06M	-386.26M	-391.83M	-396.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3.27M	-3.64M	-4.06M	-4.44M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.47M	6.29M	-13.04M	-8.43M	-15.45M	-17.2M	-7.9M	-8.18M	-7.09M	-3.88M
Operating CF Margin %	-4.47%	0.42%	-60.64%	-1.43%	-4.28%	-3.56%	-5.18%	-136.38%	-7092%	-
Operating CF Growth %	-0.27%	1.84%	-3.07%	0.35%	-0.83%	-0.11%	0.54%	-0.04%	0.13%	0.45%
Net Income	-11.28M	5.13M	-14.31M	-9.02M	-16.46M	-18.24M	-8.78M	-10.21M	-5.57M	-4.71M
Depreciation & Amortization	358K	377K	417K	380K	244K	292K	221K	196K	112K	5K
Stock-Based Compensation	1.03M	1.04M	1.69M	1.56M	572K	7K	1.5M	997K	1.01M	0
Deferred Taxes	0	-1.04M	-619K	-134K	-1.34M	-760K	-661K	0	0	0
Other Non-Cash Items	4.51M	214K	141K	-803K	572K	482K	-5K	452K	-1.73M	-2K
Working Capital Changes	-2.08M	567K	-357K	-408K	961K	1.02M	-219K	378K	-916K	823K
Change in Receivables	-245K	-245K	3.52M	-1.67M	744K	186K	642K	76K	-10K	1.05M
Change in Inventory	83K	0	0	31K	264K	287K	35K	187K	0	0
Change in Payables	-250K	-1.14M	-2.19M	542K	-125K	1.1M	-1.19M	-751K	-476K	-145K
Cash from Investing+	-133K	-171K	-175K	-416K	-256K	-540K	-23K	0	732K	0
Capital Expenditures	-133K	-171K	-175K	-416K	-256K	-540K	-23K	0	-2K	0
CapEx % of Revenue	0.08%	0.01%	0.81%	0.07%	0.07%	0.11%	0.02%	-	2%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-133K	-133K	-175K	-579K	-267K	-540K	-23K	0	734K	0
Cash from Financing+	-14K	27K	6.73M	10.62M	11.27M	17.93M	8.84M	4.98M	10M	-62K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-285K	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	27K	0	3.6M	1.6M	7.24M	0	4K	0	-62K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.6M	6.12M	-13.21M	-8.85M	-15.7M	-17.74M	-7.92M	-8.18M	-7.09M	-3.88M
FCF Margin %	-4.55%	0.41%	-61.46%	-1.5%	-4.35%	-3.67%	-5.19%	-136.38%	-7094%	-
FCF Growth %	-0.29%	1.81%	-3.16%	0.33%	-0.77%	-0.13%	0.55%	-0.03%	0.13%	0.45%
FCF per Share	-68.21	51.36	-112.06	-46.66	-9.60	-8.88	-3.97	-12.18	-9.43	-4.32
FCF Conversion (FCF/Net Income)	0.66x	1.23x	0.91x	0.93x	0.96x	0.83x	0.97x	0.80x	1.27x	0.82x
Interest Paid	0	0	298K	471K	432K	295K	0	0	21K	13K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-144.59%	50.89%	-203.69%	-234.73%	-389.38%	-834.96%	-187.17%	-313.09%	-139.14%	-103.63%
Return on Invested Capital (ROIC)	-	-	-	-700.73%	-1010.24%	-	-	-	-	-12206.25%
Gross Margin	-179.77%	59.34%	-4387.44%	90.9%	64.33%	90.24%	86.96%	-226.67%	100%	-
Net Margin	-674.99%	34.09%	-6654.42%	-152.65%	-445.56%	-428.44%	-531.72%	-16961.67%	-556900%	-
Debt / Equity	-	-	7.68x	0.63x	3.10x	0.23x	0.06x	0.14x	0.09x	-
Interest Coverage	-	117.38x	-39.30x	-9.32x	-17.42x	-9.56x	-	-	-	-
FCF Conversion	0.66x	1.23x	0.91x	0.93x	0.96x	0.83x	0.97x	0.80x	1.27x	0.82x
Revenue Growth	-54.17%	801.56%	-98.57%	2649.3%	-38.91%	33.98%	-68.46%	-96.07%	-98.33%	-100%

Revenue by Segment

	2019	2020	2021	2022	2023
Grant	2.29M	4.3M	-	497K	183K
Grant Growth	-	87.73%	-	-	-63.18%
License and Service	-	-	-	60K	1K
License and Service Growth	-	-	-	-	-98.33%
Grant revenue	-	-	1.28M	-	-
Grant revenue Growth	-	-	-	-	-
Product revenue	-	-	236K	-	-
Product revenue Growth	-	-	-	-	-
License revenue	-	-	13K	-	-
License revenue Growth	-	-	-	-	-
Manufactured Product Other	1.01M	528K	-	-	-
Manufactured Product Other Growth	-	-47.51%	-	-	-
License And Service	315K	11K	-	-	-
License And Service Growth	-	-96.51%	-	-	-

Frequently Asked Questions

Growth & Financials

Titan Pharmaceuticals, Inc. (TTNP) reported $0.0M in revenue for fiscal year 2024. This represents a 100% decrease from $4.1M in 2011.

Titan Pharmaceuticals, Inc. (TTNP) saw revenue decline by 100.0% over the past year.

Titan Pharmaceuticals, Inc. (TTNP) reported a net loss of $2.8M for fiscal year 2024.

Dividend & Returns

Titan Pharmaceuticals, Inc. (TTNP) has a return on equity (ROE) of -103.6%. Negative ROE indicates the company is unprofitable.

Titan Pharmaceuticals, Inc. (TTNP) had negative free cash flow of $2.7M in fiscal year 2024, likely due to heavy capital investments.